Shares of Swedish Orphan Biovitrum AB rallied after the Stockholm-listed biopharmaceutical firm posted a strong second quarter and raised its full-year targets for both top-line growth and profitability.
Trading in Sobi advanced 4.3% to SEK 475.6 following the results. The company reported total revenue of SEK 7.84 billion for the second quarter, representing a 29% increase at constant exchange rates from SEK 6.17 billion in the same period a year earlier.
Alongside the quarterly figures, Sobi upgraded its outlook for the full year. Revenue growth is now expected to be in the mid-to-high-teens percentage range at constant exchange rates, revised upward from a prior projection of low double-digit growth. The company also raised its adjusted EBITA margin guidance to the mid-to-high-30s percentage of revenue, up from a previous mid-30s margin assumption.
The revenue uplift was broad-based across Sobi’s two principal franchises. Haematology sales rose 27% at constant exchange rates to SEK 5.73 billion, with notable strength in Altuvoct, which more than doubled to SEK 1.55 billion, and Doptelet, which increased to SEK 1.63 billion. Immunology revenue grew 37% at constant exchange rates to SEK 1.71 billion, led by Gamifant and Kineret.
Analyst sentiment around the company was supportive at the time of the release, with 10 analysts recommending a buy and none issuing sell recommendations, yielding an overall Buy consensus rating.
Market-wide moves provided little explanatory power for Sobi’s stock action. U.S. equities were mixed on the day, with the S&P 500 marginally lower, the Nasdaq modestly down and the Dow slightly higher. The relevant local benchmark for the company is the OMX Stockholm 30 Index, and those broader moves did not meaningfully account for the Stockholm-listed shares’ advance.
Sobi’s share price has rebounded sharply from its 52-week low of SEK 261.2. The intraday high of SEK 477 placed the stock within striking distance of its 52-week peak at SEK 487.
The combination of a clear Q2 beat and a material upgrade to full-year guidance provided the fundamental rationale for investor buying. Management pointed to accelerating growth across its strategic portfolio and improvement in profitability metrics earlier than previously anticipated, which market participants interpreted as a signal that Sobi could sustain its rare-disease growth trajectory through the remainder of 2026.
Contextual note: The facts presented here reflect the company’s reported results, guidance changes and market reaction as released with the quarterly announcement.